Blockchain Registration Transaction Record

Kairos Pharma Wins Award for Drug Resistance Breakthroughs

Kairos Pharma wins 2026 GHP Magazine award as USA leader in drug resistance development. ENV-105 targets CD105 to reverse resistance in cancer. Learn more about KAPA stock and clinical trials.

This news matters because drug resistance is a critical challenge in cancer treatment, often leading to relapse and reduced effectiveness of therapies. Kairos Pharma's focus on targeting drug resistance through its lead candidate ENV-105 could revolutionize how resistant cancers are treated, potentially extending the lives of patients with prostate and lung cancers. For the broader oncology field, this represents a shift towards more durable and effective treatments, offering hope to millions of patients worldwide.